Abstract Purpose: Dihydropyrimidine dehydrogenase (DPD) deficiency is critical in the predisposition to 5-fluorouracil dose-related toxicity. We recently characterized the phenotypic [2-
rate-limiting enzyme in uracil and 5-fluorouracil (5-FU) catabolism, converting >80% of an administered dose of 5-FU to inactive metabolites (1, 2) . The initial step of catabolism is mediated by DPD converting 5-FU to 5-dihydrofluorouracil, with subsequent catabolism by dihydropyrimidinase and h-ureidopropionase enzymes to ultimately produce fluoroh-alanine, ammonia, and CO 2 . The latter final metabolic endproducts are excreted in the urine and breath (3) .
The pharmacogenetic syndrome of complete and partial DPD deficiency is prevalent in f0.1% and 3% to 5% of the general population, respectively (4) . DPD deficiency is a significant pharmacogenetic factor in the predisposition of cancer patients to increased risk of altered 5-FU pharmacokinetics and associated toxicity. Specifically, 60% of patients presenting with severe 5-FU-related hematologic toxicity showed reduced DPD activity (5) .
Recent studies have investigated the predictive value of the ratio of plasma dihydrouracil area under the curve (AUC) to uracil AUC (DUUR) for the assessment of DPD activity and potential individualization of 5-FU therapy. Specifically, 5-FU dose optimization may be based on the plasma DUUR observed before 5-FU administration (6) . Jiang et al. have also showed that the pre-5-FU treatment DUUR may be a good index of DPD activity (7, 8) .
Our laboratory recently reported the rapid noninvasive phenotypic [2- 13 C]uracil breath test (UraBT) for assessment of DPD activity with 96% specificity and 100% sensitivity (9) . Application of the UraBT to a large population of cancer-free subjects (n = 255) showed an observed 86% sensitivity (with 12 of 14 DPD-deficient subjects identified as DPD deficient) and 99% specificity (with 239 of 241 subjects with DPD activity in the reference range identified as normal; ref. 10) . To date, however, the clinical relationship between pharmacokinetics of the [2- 13 C]uracil probe substrate and its metabolites in plasma and breath remains to be elucidated.
Based on our initial characterization of the UraBT, we hypothesize that (a) [2- 13 C]uracil metabolite pharmacokinetic variables in the breath and plasma are reflective of DPD activity and (b) breath 13 CO 2 concentrations as measured through the UraBT correlate with plasma [2- 13 C]uracil metabolite pharmacokinetics. In the present study, we provide a detailed characterization of the UraBT showing the relationship among breath 13 CO 2 metabolite formation, plasma [2- 13 C]dihydrouracil formation, [2- 13 C]uracil clearance, and DPD activity.
Materials and Methods
Subjects. Thirty-one subjects (16 men and 15 women; ages 19-70 years) participated in this institutional review board -approved pharmacokinetic examination that was conducted at the General Clinical Research Center at the University of Alabama at Birmingham. Eight subjects were cancer patients who were referred by their oncologist due to known or suspected DPD deficiency. Twenty-three subjects were participants from the University of Alabama at Birmingham campus who volunteered for examination after reading an institutional review board -approved advertisement placed in the campus newspaper. Due to the rarity of DPD deficiency in the general population, we included six DPD-deficient individuals previously phenotyped [UraBT and DPD peripheral blood mononuclear cell (PBMC) radioassay] and genotyped (denaturing high-performance liquid chromatography analysis of the DPYD gene) in the current pharmacokinetic examination (9) . Subjects with a history of gastric (i.e., dyspepsia) or respiratory (i.e., asthma) disease were excluded from the study.
DPD radioassay. PBMC DPD activity was determined for all subjects as described previously (11, 12) . To minimize interassay variation in enzyme activity, 60 mL whole blood was collected into heparinized vacutainers at f12 p.m. on the day of testing and processed within 10 minutes of collection. After Ficoll separation of whole blood, isolated PBMCs were washed with PBS and lysed. The cytosol was collected after cellular debris was removed by centrifugation. The concentration of cytosolic protein was quantified by the Bradford method (13) . A reaction mixture containing 250 Ag cytosolic protein, NADPH, buffer A, and [6] [7] [8] [9] [10] [11] [12] [13] [14] C]-5-FU was incubated for 30 minutes. Every 5 minutes, 130 AL aliquots were removed and added to an equal volume of ice-cold ethanol. This mixture was incubated overnight at À80jC, thawed, and filtered to remove protein before high-performance liquid chromatography analysis. [6- 14 C]-5-FU and [6-
14
C]-5-FUH 2 were separated and quantified using a previously described reverse-phase high-performance liquid chromatography method (11, 12) . The amount of [6- 14 C]-5-FUH 2 formed at each time point (Y axis) was plotted against time (X axis). Linear regression analysis was used to calculate the equation of the line and determine the formation rate of [6] [7] [8] [9] [10] [11] [12] [13] [14] C]-5-FUH 2 . DPD enzyme activity was calculated by dividing the formation rate of [6] [7] [8] [9] [10] [11] [12] [13] [14] C]-5-FUH 2 by the amount of protein used in the reaction mixture (i.e., nmol/min/ mg protein). Subjects were considered to be partially DPD deficient by radioassay when their fresh PBMC DPD activity was <0.18 nmol/min/ mg protein (11) . Subjects were considered to be profoundly DPD deficient by radioassay when their PBMC DPD activity was undetectable.
Uracil breath test. The UraBT principle and detailed methodology has been described previously (9) . At f8 a.m. on the day of testing, fasting subjects were weighed and an aqueous solution containing 6 mg/kg [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]uracil (Cambridge Isotope Laboratories, Inc., Andover, MA) was prepared. Subjects donated three baseline breath samples into 1.2 L breath bags (Otsuka Pharmaceutical, Tokushima, Japan) followed by oral administration of the [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]uracil solution. Post-dose breath samples were collected into 100 mL breath bags (Otsuka Pharmaceutical) during the 180-minute period immediately following [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]uracil administration. IR spectrophotometry (UBiT-IR 300 , Meretek, Lafayette, CO) was used to measure breath 13 CO 2 concentrations, which were reported in delta over baseline (DOB) notation as described previously (9) . Breath profiles were constructed by plotting the concentration of 13 CO 2 in breath at each time point (Y axis) against time (X axis). The percent dose of [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]uracil recovered in the breath as 13 CO 2 (PDR) was calculated as described elsewhere (14) . Breath 13 CO 2 maximum plasma concentration (C max ), time to C max (T max ), and DOB 50 ( 13 CO 2 concentration in breath 50 minutes after [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]uracil administration) were determined by inspection of breath profiles (9) . Subjects showing a DOB 50 < 128.9 DOB were classified as DPD deficient (9) . Subjects showing a DOB 50 z 128.9 DOB were classified as having normal DPD activity (9) .
Liquid chromatography-tandem mass spectrometry analysis of plasma [2- 13 C]uracil administration. Blood was immediately processed after collection and plasma was isolated as follows: 3 mL whole blood was centrifuged at 4jC for 10 minutes at 2200 Â g; plasma was immediately pipetted into polypropylene tubes and then stored at À80jC until analysis by liquid chromatographytandem mass spectrometry.
Detection and quantification of plasma [2-13 C]uracil and [2-
13 C]dihydrouracil was done following minor modification of a previously described liquid chromatography-tandem mass spectrometry method (15 N 2 ]dihydrouracil (Cambridge Isotope Laboratories) were used as internal standards. Plasma protein was precipitated by adding 500 AL of a saturated ammonium sulfate solution and 4 mL acetronitrile to 500 AL plasma. Following centrifugation, the organic layer was collected, evaporated, and reconstituted in 200 AL purified water. The mixture was injected into the liquid chromatographytandem mass spectrometry system (TSQ7000, Thermo Finnigan, San Jose, CA). [2- 13 C]Uracil and [2-13 C]dihydrouracil were separated on a Develosil RAPQUEOUS reverse-phase column (5 Am, 2.0 Â 150 mm; Normura Chemical Co., Ltd., Seto, Japan) in a mobile phase of 1:99 (v/v) methanol/water. Atmospheric pressure chemical ionization was used to form protonated analytes and fragment them. Selected reaction monitoring was used to detect the fragmentation pattern of parent and daughter ions and quantify the concentrations of [2- CO 2 in breath. Calculated pharmacokinetic variables were AUC H , C max , T max , apparent clearance (CL/F), terminal apparent distribution volume (V z /F), and elimination half-life (t 1/2 ). AUC H was determined using the trapezoidal rule (16) . C max and T max were taken directly from the observed concentration-time data. CL/F was calculated as dose/AUC H . V z /F was calculated as dose divided by the product of terminal elimination rate constant, k z , and AUC H . The elimination rate constant was determined by linear regression of the terminal elimination phase concentration-time points; t 1/2 was calculated as ln (2) 13 C]dihydrouracil concentrations and pharmacokinetic variables between subjects with normal DPD activity and subjects with partial DPD deficiency were assessed by bootstrap t tests of hypotheses using PROC MULTTEST in SAS version 9.1. The bootstrap Ps were compared with the raw Ps to assess nonnormality of inferences. If the bootstrap P was close to the normality-assuming P, we concluded that nonnormality was not a concern for the particular variable. For comparisons between the subjects with normal DPD activity and the one subject with profound DPD deficiency, we used the t test to perform a single mean comparison to test the mean of subjects with normal DPD activity for each variable against the value for the profoundly DPD-deficient individual. Correlations among UraBT DOB 50 , PBMC DPD activity, and plasma [2- 13 C]uracil and [2-13 C]dihydrouracil pharmacokinetic variables were evaluated using Pearson's correlation coefficient. For all analyses, P < 0.05 was deemed statistically significant.
Results
Determination of PBMC DPD activity. The DPD enzyme activity was determined for all subjects (mean F SD). Nineteen subjects showed normal DPD activity (0.27 F 0.06 nmol/min/ mg), 11 subjects showed partial DPD deficiency (0.11 F 0.05 nmol/min/mg), and 1 subject showed profound deficiency (undetectable DPD activity).
Detection of DPD deficiency by UraBT. UraBT indices (mean F SD) obtained in subjects with normal and reduced DPD activity are summarized in Table 1 . The UraBT showed 100% agreement with the PBMC radioassay. Subjects with DPD activity in the reference range showed UraBT DOB 50 z 128.9 DOB. All partially and profoundly DPD-deficient subjects showed DOB 50 < 128.9 DOB. Altered breath 13 CO 2 concentration-time profiles were also observed in all DPD-deficient subjects. Specifically, profoundly and partially DPD-deficient subject(s) showed an increased UraBT T max and reduced UraBT 13 CO 2 C max , DOB 50 , AUC, and PDR compared with subjects with normal DPD activity (all Ps < 0.05).
UraBT DOB 50 also showed significant correlation with PBMC DPD activity (Fig. 1A) .
Comparison of plasma [2-13 C]uracil pharmacokinetics in subjects with normal and reduced PBMC DPD activity. Plasma [2- 13 C]uracil pharmacokinetic variables (mean F SD) obtained from subjects with normal and reduced DPD activity are summarized in Table 2 . [2-
13 C]Uracil was detectable in the plasma of most subjects 5 minutes after oral administration ( Fig. 2A) . No statistically significant differences were observed in plasma [2- 13 C]uracil C max between subjects with normal activity and those with partial or profound DPD deficiency. No significant difference was observed in plasma [2- 13 C]uracil T max from subjects with normal DPD activity and subjects with partial DPD deficiency. However, a significant difference was observed in plasma [2- 13 C]uracil T max from the subjects with normal DPD activity and the profoundly DPD-deficient subject.
Reduced [2-13 C]uracil catabolism was observed in all DPDdeficient subjects (Fig. 2A) . Both profoundly and partially DPD-deficient subject(s) showed increased plasma [2-
13 C]uracil t 1/2 and AUC and reduced plasma [2- 13 C]uracil clearance compared with subjects with normal DPD activity (all Ps < 0.05).
PBMC DPD activity was significantly correlated with several pharmacokinetic variables of uracil catabolism. Specifically, PBMC DPD was significantly correlated with plasma [2-
13 C]uracil clearance (Fig. 1B ) and inversely correlated with plasma [2-
13 C]uracil AUC and t 1/2 (all Ps < 0.05; Table 3 ).
The UraBT DOB 50 were also significantly correlated with several pharmacokinetic variables of uracil catabolism. Specifically, the UraBT DOB 50 were significantly correlated with plasma [2- 13 C]uracil clearance and inversely correlated with plasma [2- 13 C]uracil AUC (Fig. 1C) and t 1/2 (all Ps < 0.05; Table 3 ). Table 4 . Altered plasma [2- 13 C]dihydrouracil concentrations were observed in DPDdeficient subjects (Fig. 2B) . The profoundly deficient subject showed plasma [2- 13 C]dihydrouracil concentrations beneath the limit of detection; thus, pharmacokinetic variables could not be determined. Partially deficient subjects showed significantly decreased plasma [2- 13 C]dihydrouracil C max and increased plasma [2- 13 C]dihydrouracil T max and t 1/2 compared with subjects with normal DPD activity (all Ps < 0.05). Partially deficient subjects also showed a significant reduction in the proportion of [2- 13 C]uracil metabolized to [2- 13 C]dihydrouracil, [2-13 C]dihydrouracil appearance rate, amount of [2- 13 C]dihydrouracil formed, and plasma DUUR (all Ps < 0.05).
[2-13 C]Dihydrouracil formation and concentrations were significantly correlated with PBMC DPD activity (Table 3) . Specifically, PBMC DPD activity was significantly correlated with the proportion of [2- 13 C]uracil metabolized to [2- 13 C]dihydrouracil, [2-13 C]dihydrouracil appearance rate, amount of [2- 13 C]dihydrouracil formed, plasma C max , and plasma DUUR (all Ps < 0.05). PBMC DPD activity was also inversely correlated with plasma [2-
13 C]dihydrouracil T max (P < 0.05).
[2-13 C]Dihydrouracil formation and concentrations were significantly correlated with UraBT DOB 50 (Table 3 ). In particular, UraBT DOB 50 were significantly correlated with the proportion of [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]uracil metabolized to [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]dihydrouracil, [2- 13 C]dihydrouracil appearance rate, amount of [2-13 C]dihydrouracil formed (Fig. 1D) , plasma DUUR, and plasma [2- 13 C]dihydrouracil C max (all Ps < 0.05). UraBT DOB 50 were inversely correlated with plasma [2- 13 C]dihydrouracil T max (P < 0.05).
Discussion
Identification of DPD-deficient cancer patients is important in optimizing 5-FU chemotherapy and minimizing lifethreatening dose-related toxicity. We developed the UraBT, which may be used to screen cancer patients for DPD deficiency before administration of 5-FU (9) . The principle of the UraBT was based on earlier metabolic studies that showed uracil and 5-FU are both degraded by the enzymes of the pyrimidine catabolic pathway, with the DPD enzyme having similar affinities for 5-FU and uracil (18 -20) . These studies provided a basis for use of the nontoxic [2- 13 C]uracil probe substrate in the UraBT to assess in vivo pyrimidine catabolism. Our initial examination of 50 volunteers and 8 DPD-deficient subjects suggested that the UraBT may be a good indicator of DPD activity. In this study, significantly reduced breath 13 CO 2 concentrations (DOB 50 , C max , AUC, and PDR) were observed from enrolled subjects with DPD deficiency versus those with normal DPD activity. Furthermore, the UraBT detected DPD deficiency with 96% specificity and 100% sensitivity (9) . A more recent study of 255 subjects has corroborated our initial findings, with the UraBT showing 99.2% specificity and 85.7% sensitivity for detecting DPD deficiency (10) . In the present study, we further validate the UraBT in a population of subjects with normal and reduced DPD activity by comparing breath 13 CO 2 kinetic profiles to plasma [2- 13 C]uracil and [2-13 C]dihydrouracil kinetics.
Examination of plasma [2-13 C]uracil concentration-time profiles showed that orally administered [2- 13 C]uracil was rapidly absorbed and detected in the plasma of most subjects within 5 minutes of administration. This observation is in agreement with an earlier animal study, which also reported rapid absorption following oral administration of [2- 13 C] uracil (15) .
Following absorption of [2-13 C]uracil in subjects with normal DPD activity, the [2- 13 C]uracil was observed to peak Research.
on May 29, 2017. © 2006 American Association for Cancer clincancerres.aacrjournals.org Downloaded from at f28.9 F 9.5 minutes. Subsequently, plasma concentrations decreased reflecting both metabolism and elimination as indicated by the appearance of [2- 13 C]dihydrouracil in the plasma (within 10 minutes) and 13 CO 2 in the breath. Following absorption of [2- 13 C]uracil in subjects with partial and profound DPD deficiency, significant differences in both metabolism and elimination were noted as indicated by decreased plasma [2- 13 C]uracil clearance, decreased appearance of [2- 13 C]dihydrouracil in plasma, and decreased 13 CO 2 concentrations in breath compared with subjects with normal DPD activity. In particular, a significant reduction in the appearance of [2- 13 C]dihydrouracil in the plasma was observed between partially DPD-deficient subjects and subjects with normal DPD activity, whereas the profoundly DPD-deficient subject showed no detectable plasma [2- 13 C]dihydrouracil (Fig. 2B) . These results suggest that the [2- 13 C]dihydrouracil appearance rate may be a direct indicator of DPD activity. This conclusion is based on the rationale that DPD-mediated metabolism of [2- 13 C]uracil to [2-13 C]dihydrouracil is the exclusive and singular source of plasma [2- 13 C]dihydrouracil, with 1 mol [2-
13 C]uracil being converted to 1 mol [2-
Several previous studies of DPD-deficient cancer patients have reported reduced 5-FU clearance with an increased 5-FU t 1/2 and AUC after oral and i.v. 5-FU administration (21 -24).
Our observations with orally administered [2- 13 C]uracil parallel these findings. Specifically, we observed significantly reduced plasma [2- 13 C]uracil clearance in partially and profoundly DPD-deficient subjects, which resulted in increased plasma [2- 13 C]uracil t 1/2 and AUC compared with subjects with normal DPD activity. Several clinical studies of plasma 5-FU concentrations in cancer patients have also observed inverse correlations between plasma 5-FU concentrations or t 1/2 and DPD activity as well as positive correlations between 5-FU clearance and DPD activity (25, 26) . Our observations with orally administered [2- 13 C]uracil also parallel these studies. We reported inverse correlations between PBMC DPD activity and both plasma [2- 13 C]uracil AUC and t 1/2 as well as a positive correlation between PBMC DPD activity and plasma [2- 13 C]uracil clearance. Using [2-13 C]uracil, we noted significant correlations between PBMC DPD activity and several [2- 13 C]dihydrouracil pharmacokinetic variables. In particular, PBMC DPD activity was significantly correlated with plasma [2- 13 C]dihydrouracil appearance rate, amount of [2- 13 C]dihydrouracil formed, and [2-
13 C]dihydrouracil C max . In turn, a significant correlation between DPD-mediated plasma [2- 13 C]dihydrouracil formation and breath 13 CO 2 formation was observed, suggesting that the UraBT 13 CO 2 kinetic variables are an accurate and sensitive index of systemic DPD activity. This conclusion is supported by the biochemical pathway of uracil catabolism where 1 mol C]Uracil (6 mg/kg) was orally administered to19 subjects with normal DPD activity,11subjects with partial DPD deficiency, and1subject with profound DPD deficiency. Following quantification of plasma [2- cP < 0.05 for both pairwise comparisons (normal DPD activity versus partial DPD deficiency and normal DPD activity versus profound DPD deficiency). bP > 0.05 for both pairwise comparisons (normal DPD activity versus partial DPD deficiency and normal DPD activity versus profound DPD deficiency). x P > 0.05 (normal DPD activity versus partial DPD deficiency). k P < 0.05 (normal DPD activity versus profound DPD deficiency). Although we observed significant correlations between PBMC DPD activity and [2-
13 C]uracil clearance as well as between PBMC DPD activity and [2-
13 C]dihydrouracil formation, not all the variability in these pharmacokinetic variables could be attributed to variability in PBMC DPD activity. In fact, wide variation in DPD activity levels have been observed throughout various tissues (i.e., PBMC, kidney, colon, and liver), with the primary site of pyrimidine catabolism being the liver. Hence, the 13 CO 2 detected in our assay should be primarily formed in the liver. However, ethical considerations prevented the measurement of hepatic DPD in this human study. An examination of the relationship present between the UraBT and hepatic DPD activity in dogs suggested that systemic DPD activity may be more accurately reflected in breath 13 CO 2 concentrations than PBMC DPD activity (15) . Hepatic DPD activity was significantly correlated with systemic DPD-mediated reduction of [2- 13 C]uracil as measured in breath 13 CO 2 concentrations (r = 0.9999; ref. 15 ). This animal study suggests that hepatic DPD activity should strongly correlate with breath 13 CO 2 formation in humans.
5-FU is characterized by a narrow therapeutic index and significant interpatient variability in its pharmacokinetics, which are both implicated in the wide interpatient variation in efficacy and toxicity (6, 26 -29) . These observations have led to the development of assays to measure plasma DUUR (or 5-dihydrofluorouracil/5-FU ratio) as a potential index on which 5-FU dose individualization strategies may be based (6, 28, 30) . Notably, Jiang et al. suggested the importance of monitoring the formation of dihydrouracil under physiologic conditions, by examining the DUUR, to assess variability in DPD activity and 5-FU pharmacokinetics (7). Our results also parallel their observations. Specifically, we observed a significant correlation between PBMC DPD activity and DUUR. We also observed a significant correlation between UraBT DOB 50 and DUUR.
In summary, we evaluated the UraBT with respect to PBMC DPD activity and plasma [2- 13 C]uracil and [2-13 C]dihydrouracil concentrations in subjects with normal and reduced DPD activity. In the present study, we showed significant differences in [2-13 C]uracil and [2-13 C]dihydrouracil kinetics and UraBT 13 CO 2 concentrations (e.g., DOB 50 ) in subjects with decreased DPD activity versus those with normal DPD activity. The significant correlations between DPD activity and either plasma [2- 13 C]uracil clearance, [2-13 C]dihydrouracil formation, or 13 CO 2 breath concentrations provide further support that the UraBT may be useful for assessment of DPD deficiency before administration of 5-FU.
